Key result
Diazoxide is approximately 90% bound to human plasma proteins, accounting for its 26-hour half-life and the requirement for rapid intravenous injection to achieve maximal hypotensive action.
Population
Pharmacological study of diazoxide binding to human albumin
Design
Other
Authors
Loading...
May guide rapid IV dosing in hypertensive crises; leaves open clinical validation of protein-binding effects.
The high degree of protein binding of diazoxide explains its long plasma half-life and the necessity for rapid intravenous injection to achieve maximal hypotensive effect.
Sellers et al. (1969) studied severe hypertension. Diazoxide was evaluated on Protein binding and pharmacokinetics. Diazoxide is approximately 90% bound to human plasma proteins, accounting for its 26-hour half-life and the requirement for rapid intravenous injection to achieve maximal hypotensive action.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: